Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
News|Articles|December 23, 2025
Prostate Cancer Screening After Biden’s Diagnosis: What Urologists Are Seeing in Practice
Author(s)Hannah Clarke, Benjamin Saylor
Fact checked by: Patrick Campbell
Results of an exclusive Urology Times survey indicate heightened concern among older men about prostate cancer screening.
Advertisement
Advertisement
The May 19, 2025, announcement of former President Joe Biden’s prostate cancer diagnosis placed renewed attention on screening, detection, and treatment of a disease that remains a leading cause of cancer-related death among US men. In the days and weeks that followed, urologists across the country began to notice subtle but meaningful changes in patient behavior and clinical conversations.
Related to this article
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.
From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Oral icotrokinra sustained clearance at scalp, genital, hand/foot, and nail sites through Week 112 in ICONIC-TOTAL, with no rise in adverse event rates.
Advertisement
Advertisement